HIV Diagnosis Market to Reach .7 Billion Globally, By 2032 at 3.9% CAGR: Allied Market Research

Rise in the number of HIV cases coupled with the launch of novel testing kits, specifically home-based or self-testing kits, is expected to boost the market growth. 

Wilmington, New Castle, Delaware, March 14, 2024 (GLOBE NEWSWIRE) — Allied Market Research published a report, titled, HIV Diagnosis Market by Mode (Self-test and Lab-based), Test Type (Antibody/Antigen Test, Viral load test/Nucleic Acid Test, CD4 test, and Test for Early Infant Diagnosis), and End Use (Diagnostic Laboratories, Hospitals & Clinics, and Home Settings): Global Opportunity Analysis and Industry Forecast, 2023-2032″. According to the report, the global HIV Diagnosis industry generated $1.9 billion in 2022 and is anticipated to generate $2.7 billion by 2032, witnessing a CAGR of 3.9% from 2023 to 2032.    

Prime determinants of growth  

The market is primarily driven by the spread tof HIV hrough sexual contact, injecting of illicit drugs or use of shared needles, and contact with infected blood. HIV also can spread from parent to child during pregnancy, breastfeeding or childbirth. HIV destroys white blood cells called CD4 T cells, which play a vital role in aiding the body fight the disease. CD4 cells are important as fewer CD4 T cells leads to weaker immune system.   

Request Sample of the Report on HIV Diagnosis Market Forecast 2032 

In addition, increase in R&D activities since 2023 for developing novel self-test kits which are affordable in lower income countries such as in the Africa region such as Eswatini, Botswana, and Lesotho further boosts the HIV diagnosis market growth.   

Report coverage & details:   

Report Coverage     Details    
Forecast Period     2023–2032    
Base Year     2022    
Market Size In 2022     $1.9 Billion    
Market Size In 2032     $2.7 Billion    
CAGR      3.9%    
No. Of Pages In Report     290   
Segments Covered     Mode, Test Type, End Use, And Region    
Drivers      Rise In Number Of HIV Cases And Launch Of Novel Self-Test Kits  
Increase In Number Of Blood Transfusion And Blood Donations  
Increase In Government Initiatives  
Opportunities     Emerging Economies Offer Lucrative Opportunities  
Restraint     High Cost Of Nucleic Acid Test  

Want to Explore More, Connect to our Analyst –  

Recession Impact 

  • During a recession, individuals and governments might tighten their budgets, leading to reduced healthcare spending. This could affect patients’ ability to access and afford HIV testing kits, potentially leading to moderate decreased demand for diagnosis kits.  

The lab-based segment to maintain its lead position during the forecast period  

By mode, the lab-based test dominated the market in 2022 and is expected to continue this trend during the forecast period. Lab-based testing is more accurate and individuals who test positive can get help from the healthcare professional regarding the disease monitoring and progression right in the lab itself. In addition, lab-based tests give results in a few days as compared to self-tests, which take around 7-8 days. Lab-based HIV diagnosis is often included in existing healthcare systems, making it accessible in various healthcare settings, including hospitals, clinics, and laboratories. This incorporation facilitates coordination of care, linkage to treatment and support services, and follow-up monitoring for individuals diagnosed with HIV.  
The viral load test/Nucleic acid test segment to maintain its lead position during the forecast period 

By test type, the viral load test/nucleic acid test segment is expected to register a faster CAGR of 4.6% during the forecast period, as many countries are embracing viral load testing for treatment monitoring. This approach could be further facilitated by employing viral load point-of-care technologies and dried blood spots. Further, based on Antibody/Antigen Test, HIV-1 Antibody Confirmatory Tests are expected to garner major share in 2022 and are expected to continue this trend during the forecast period.  
The diagnostic laboratory segment to maintain its lead position during the forecast period 

By end use, the diagnostic laboratory segment dominated the market in 2022 and is expected to grow with a higher CAGR of 4.2% during forecast period. The growth in diagnostic laboratory HIV diagnosis has increased in recent years considering the social stigma and discrimination behind such illnesses. Hence, individuals with HIV often visit diagnostic laboratories or private clinics to avoid the negative emotional well-being and mental health of people living with HIV.  
North America to maintain its dominance by 2032 

By region, North America dominated the market in 2022 and is expected to continue this trend during the forecast period, owing to the presence of majority of the HIV testing manufacturers in the U.S. as well as the support from government and other organizations related to awareness programs and reduction in prices of testing kits. However, LAMEA is expected to grow with a faster CAGR of 6.4% during the forecast period. Africa is the epicenter of HIV globally and the cases are growing at a faster rate in certain African countries. For instance, according to UNAIDS, an estimated 67% of the population in Sub-Saharan Africa (SSA) were living with HIV as of 2021. Further, in key Sub-Saharan Africa, key populations accounted for about 51% of new infections in 2021.   

For Procurement Information – 

Leading Market Players

  • Abbott  
  • Gilead Sciences Inc.  
  • Merck & Co. Inc.  
  • Beckman Coulter Inc.  
  • Mylan N.V.  
  • F. Hoffman-La Roche Ltd.  
  • Siemens Healthcare GmbH  
  • QIAGEN  
  • Bio-Rad Laboratories Inc.  
  • Hologic  
  • Novartis AG   

The report provides a detailed analysis of these key players in the global HIV diagnosis market. These players have adopted strategies such as product launch to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.     

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research: 

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. 

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: 

About Allied Market Research: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. 

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.  

David Correa 

1209 Orange Street, 

Corporation Trust Center, 

Wilmington, New Castle, 

Delaware 19801 USA. 

Toll Free: +1-800-792-5285 

Int’l: +1-503-894-6022 

UK: +44-845-528-1300 

Hong Kong: +852-301-84916 

India (Pune): +91-20-66346060 

Fax: +1-855-550-5975 

[email protected]   


Follow Us on: LinkedIn Twitter 

Primary Logo

Originally published at